Related by context. All words. (Click for frequent words.) 74 mucinous 73 GISTs 73 bladder cancers 73 renal cell carcinomas 72 Papillary 72 epithelial tumors 72 adenoma 72 breast carcinomas 72 adenocarcinoma 72 hamartomas 72 osteosarcomas 72 advanced adenomas 71 neoplasms 71 serous ovarian cancer 71 neoplasm 71 paragangliomas 71 hyperplastic 70 leiomyomas 70 squamous cell carcinoma SCC 70 endometrial cancers 70 seminomas 70 invasive ductal 70 breast carcinoma 70 urothelial carcinoma 70 papillary 70 gastric cancers 69 lobular carcinoma 69 pulmonary metastases 69 lobular carcinomas 69 colorectal carcinoma 69 HGPIN 69 carcinoid 69 gastric adenocarcinoma 69 carcinoid tumors 69 ALK mutations 69 basal cell carcinoma BCC 69 advanced adenoma 69 lymph node metastases 69 gastric carcinoma 69 micrometastases 69 pheochromocytoma 69 PNET 69 tumoral 69 hepatocellular carcinomas 69 PCa 68 sarcomatoid 68 mesotheliomas 68 pancreatic adenocarcinoma 68 neoplasias 68 activating mutations 68 atypical hyperplasia 68 invasive carcinoma 68 metastatic lesions 68 metastases 68 cell adhesion molecule 68 adenomatous polyps 68 carcinoma 68 papillary renal cell carcinoma 68 K ras mutations 68 cholangiocarcinoma 68 hepatocellular carcinoma HCC 68 premalignant 68 epithelioid 68 supratentorial 68 histological subtype 68 renal tumors 68 carcinomas 68 prostate cancer CaP 68 ADPKD 68 meningiomas 68 intestinal metaplasia 68 myeloproliferative diseases 68 malignant neoplasm 68 metaplasia 68 neoplasia 68 prostate carcinoma 67 histologically 67 neuroblastomas 67 cyclin E 67 HNSCC 67 nodal metastasis 67 hepatoma 67 colorectal carcinomas 67 osteoblastic 67 ovarian carcinoma 67 liver metastases 67 malignant prostate 67 esophageal cancers 67 situ LCIS 67 metachronous 67 paraganglioma 67 cytokeratin 67 liver metastasis 67 Adenocarcinoma 67 atherosclerotic lesions 67 schwannomas 67 Squamous 67 adenomas 67 lung carcinomas 67 ependymomas 67 histologic subtype 67 endometrioid 67 pancreatic cancers 67 cell carcinomas 67 astrocytomas 67 GSTT1 67 p# mutation 67 adenomatous 67 p# mutations 67 proximal colon 67 missense mutations 67 renal pelvis 67 myeloid 66 hypermethylated 66 GBM tumors 66 invasive ductal carcinoma 66 nonmelanoma skin cancers 66 oligodendrogliomas 66 pituitary adenomas 66 ductal 66 lobular 66 distant metastasis 66 seminal vesicle 66 esophagogastric junction 66 premalignant lesions 66 neoplastic lesions 66 MALT lymphoma 66 pleomorphic 66 intestinal polyps 66 leiomyoma 66 lymphoproliferative disorders 66 uveal melanoma 66 metastatic melanomas 66 neuroendocrine tumors 66 node metastases 66 ABCB1 66 ductal carcinomas 66 adrenocortical cancer 66 Leukemias 66 subependymal giant cell 66 carcinoids 66 SUVmax 66 malignant fibrous histiocytoma 66 HER2 positive cancers 66 colorectal adenoma 66 TCF#L# 66 monogenic 66 colorectal adenocarcinoma 66 ductal cancer 66 epithelial ovarian 66 lymph node metastasis 66 precursor lesions 66 EGFR mutations 66 ductal lobular 66 PTPN# 66 IL 1ß 66 prostate adenocarcinoma 66 lymphoid 66 HbF 65 SPINK1 65 Upregulation 65 neuroendocrine cancers 65 Fas ligand 65 pancreatic prostate 65 squamous cell carcinomas 65 promoter methylation 65 pancreatic lung 65 GNAQ 65 Glioma 65 TT genotype 65 KRAS mutations 65 lipomas 65 polyposis 65 urothelial 65 MSH2 65 chemoresistant 65 MTHFR 65 situ CIS 65 TOP2A 65 castrate resistant 65 xenograft tumors 65 cell carcinoma 65 MGUS 65 Metastatic 65 myelofibrosis polycythemia vera 65 RAV# 65 basal cell carcinomas 65 benign neoplasms 65 HER2 expression 65 c MYC 65 soft tissue sarcomas 65 lymphoid tissue 65 lung tumors 65 metastatic tumors 65 cisplatin resistant 65 Hurthle cell 65 FGFR2 65 mRNA expression 65 lung adenocarcinomas 65 nasopharyngeal carcinoma 65 invasive carcinomas 65 TGF alpha 65 infarcts 65 Immunohistochemical staining 65 hepatocellular carcinoma 65 Carcinomas 65 rs# [002] 65 squamous 65 HER2 amplification 65 trans retinoic acid 65 germline mutations 65 thyroglobulin 65 gastrointestinal stromal tumor 65 essential thrombocythemia 65 cytologically confirmed 65 osteoid 65 TIMP 65 teratoma 65 Carcinoid tumors 65 VEGF receptor 65 pancreatic endocrine 65 skeletal metastases 65 nonmetastatic 65 thyroid carcinoma 65 nonsmall cell lung cancer 65 lung cancers 65 pT2 65 hyperplasia 65 tumor xenograft models 65 lymphomas 65 neoplastic cells 65 hypermethylation 65 Epidermal Growth Factor Receptor 65 sporadic ALS 65 EGFR protein 65 papillomas 65 thyroid carcinomas 65 GBMs 65 grade cervical intraepithelial 65 GSTP1 65 GIST tumors 65 Squamous cell 64 anaplastic 64 NOTCH1 64 tumors 64 NSCLC tumors 64 myeloperoxidase 64 prostate cancers 64 resectable 64 HBeAg negative 64 HER2 overexpression 64 squamous cell lung cancer 64 c KIT 64 iNOS 64 histologies 64 IL 1beta 64 Adenomas 64 thyroid nodules 64 distant metastases 64 HER2 receptor 64 Kupffer cells 64 thymoma 64 histologic subtypes 64 colorectal neoplasms 64 pilocytic astrocytomas 64 lymphocytosis 64 neoplastic 64 papillary thyroid carcinoma 64 normal karyotype 64 colorectal liver metastases 64 Renal cell carcinoma 64 ErbB2 64 malignant lymphoma 64 osteoblast 64 Clusterin 64 hyperparathyroidism 64 syngeneic 64 somatic mutations 64 Sezary syndrome 64 Histologically 64 esophageal squamous cell carcinoma 64 Endometrial 64 eIF 4E 64 carcinoembryonic antigen 64 adenomatous polyp 64 nodal metastases 64 elevated LDH 64 rs# [004] 64 mesenteric 64 breast cancers 64 isotypes 64 squamous cell cancers 64 lymphovascular invasion 64 atrophic gastritis 64 papillary carcinoma 64 androgen receptor AR 64 malignant neoplasms 64 endometrial hyperplasia 64 NMIBC 64 solar keratosis 64 PAOD 64 homodimer 64 distal colon 64 peritoneal carcinomatosis 64 hypercalcemia 64 endobronchial 64 HLA DRB1 * 64 Sarcomas 64 lymphoid cells 64 transthyretin amyloidosis 64 colorectal gastric 64 polypoid 64 atypical ductal hyperplasia 64 lung metastases 64 PARP inhibition 64 TMPRSS2 ERG 64 ccRCC 64 Metastases 64 ovarian tumors 64 Gliomas 64 hepatocellular cancer 64 ductal adenocarcinoma 64 prostate cancer PCa 64 mTOR inhibitors 64 colorectal tumors 64 gene polymorphisms 64 malignancies 64 lymphoma subtypes 64 pheochromocytomas 64 somatostatin receptors 64 molecular abnormalities 64 chromosome #q# [002] 64 astrocytoma 64 colonic polyps 64 BRCA1 mutation carriers 64 lobular breast cancer 64 metastatic prostate 64 dysplastic 64 situ DCIS 64 antiproliferative effects 64 Cholangiocarcinoma 64 malignant lesions 64 chemokine receptor 64 TEAEs 64 axillary lymph nodes 64 carcinoid tumor 64 mesangial 64 leukaemias 64 monocyte chemoattractant protein 64 colorectal cancers 64 neurofibromas 64 breast pancreatic 64 IgA deficiency 64 malignant nodules 64 IDH1 mutation 64 metastatic neuroendocrine tumors 63 testicular cancers 63 colorectal polyps 63 leukemias lymphomas 63 HLA B# 63 metastatic colorectal 63 lobular cancer 63 ETV1 63 BMP2 63 myeloproliferative 63 grade gliomas 63 invasive lobular 63 molecular subtypes 63 monocytic 63 cervical breast 63 TP# mutations 63 pCR 63 radical nephrectomy 63 extracranial 63 familial ALS 63 papillary RCC 63 lung metastasis 63 squamous cell 63 immunohistochemical 63 Colon polyps 63 caveolin 1 63 Acute lymphoblastic leukemia 63 nonalcoholic steatohepatitis NASH 63 malignant polyps 63 EphB4 63 micrometastasis 63 immunoreactivity 63 mutated K ras 63 FGFR3 63 LRP5 63 uterine cancers 63 miR #a [001] 63 endometrial carcinoma 63 WT1 63 luminal 63 leiomyosarcoma 63 prostate pancreatic 63 colorectal pancreatic 63 epithelial ovarian cancer 63 bladder ovarian 63 inducible nitric oxide synthase 63 medically inoperable 63 chromosomal rearrangement 63 CYT# potent vascular disrupting 63 epithelial cancers 63 ERBB2 63 lung ovary 63 interferon γ 63 BCR ABL 63 oesophageal adenocarcinoma 63 cervical lymph nodes 63 extramedullary 63 Lymphocytes 63 desmoplastic 63 hypoplasia 63 HDACi 63 cutaneous melanoma 63 testicular tumors 63 vimentin 63 SSc 63 KRAS mutation 63 urothelial cancer 63 hypointense 63 colorectal tumor 63 hormone receptor negative 63 Hashimoto thyroiditis 63 GSTM1 63 intraepithelial neoplasia 63 progesterone receptor negative 63 HLA DR 63 C#Y 63 homozygotes 63 hypopharynx 63 ovarian pancreatic 63 E#F# 63 metastatic lymph nodes 63 tunica vaginalis 63 T#I [002] 63 alveolar epithelial cells 63 INCB# [003] 63 extrahepatic 63 CIN2 + 63 chromosomal aberrations 63 fallopian tube cancers 63 EGFR mutation 63 metastatic malignant 63 cellularity 63 Nodules 63 CD# + [001] 63 medullary thyroid cancer 63 gastric cardia 63 BRAF mutations 63 exocrine 63 gastrointestinal stromal tumors 63 oncoprotein 63 epithelial cell 63 Uterine fibroids 63 SGLT2 63 macroalbuminuria 63 isoenzyme 63 PIK3CA 63 acute myeloid 63 miRs 63 hepatic cirrhosis 63 proto oncogene 63 transmembrane protein 63 noncalcified 63 Gleevec resistant 63 pT3 63 inherited mutations 63 orthotopic 63 amyloid deposits 63 carotid stenosis 63 PGDH 63 bowel cancers 63 colorectal polyp 63 seminoma 63 ERK1 2 63 mammary tumors 63 NF kB pathway 63 serrated polyps 63 atypia 63 CCL# 63 gastroesophageal junction 63 mononuclear cells 63 TIMP 1 63 OGG1 63 periventricular 63 autoantibodies 63 calculi 63 medulloblastomas 62 completely resected 62 mtDNA mutations 62 breast endometrial 62 follicular thyroid cancer 62 IGFBP 3 62 clinicopathological features 62 cell lymphomas 62 ERalpha 62 KRAS mutations occur 62 oral squamous cell 62 CC genotype 62 carcinoma HCC 62 microsatellite instability 62 EpCAM 62 pulmonary metastasis 62 bone metastasis 62 Macrophage 62 abdominal adiposity 62 activin 62 tumor recurrence 62 KRAS wild 62 TSC1 62 FLT3 62 haematopoietic 62 rs# [003] 62 locoregional recurrence 62 cervical carcinoma 62 vWF 62 MLH1 62 TNF blocker therapy 62 #q#.# [001] 62 hepatic metastases 62 coding genes 62 Aß 62 ovarian breast 62 LRP6 62 basal cell nevus syndrome 62 mitogen activated protein kinase 62 fibroadenomas 62 ovarian cancers 62 TGF β 62 MACCE 62 EGFR HER2 62 lung adenocarcinoma 62 epithelia 62 EGFRvIII 62 V#F mutation 62 SLNB 62 renal fibrosis 62 progesterone receptor PR 62 Immunohistochemical analysis 62 TET2 62 activating mutation 62 hepatic steatosis 62 ductal breast cancer 62 isoenzymes 62 ependymoma 62 transitional cell carcinoma 62 immunocompetent 62 constitutively active 62 neuroendocrine carcinoma 62 MAPK pathway 62 estrogen receptor negative 62 hematologic toxicity 62 serine protease 62 lymphocytic 62 TMPRSS2 ERG fusion 62 malignant ovarian 62 Basal cell 62 cervical intraepithelial neoplasia 62 GPNMB 62 chromosome #p#.# 62 thyrotropin 62 T2DM 62 wedge resection 62 rs# [001] 62 cytotoxin 62 APOL1 62 TNFa 62 microvessel density 62 cystic lesions 62 myeloproliferative neoplasms 62 PC3 cells 62 microbleeds 62 pan HDAC inhibitor 62 ovarian lung 62 goblet cells 62 CagA 62 BRAF gene 62 thromboembolic events 62 TNFα 62 submucosa 62 VEGFR1 62 malignant pleural mesothelioma 62 Polymorphisms 62 hTERT 62 uPAR 62 Mesenchymal 62 contralateral breast 62 kDa protein 62 lung pancreatic 62 leukemia AML 62 endothelial activation 62 cardiac troponin T 62 myopathies 62 EGFR tyrosine kinase inhibitors 62 familial pancreatic cancer 62 ADAM# 62 IGFBP2 62 neuroblastoma tumors 62 lymphoid tissues 62 leukemic cells 62 stage IIIB 62 surgically resected 62 TMEM#B 62 COL#A# 62 underwent surgical resection 62 gastrointestinal cancers 62 androgen independent 62 mycosis fungoides 62 colon cancers 62 ERK signaling 62 proteoglycan 62 alkaline phosphatase ALP 62 tonsillar 62 RIP1 62 synuclein 62 bronchioloalveolar carcinoma 62 differentially expressed genes 62 retinoic acid receptor 62 missense mutation 62 transurethral resection 62 Eg5 62 FDG uptake 62 Leydig cell 62 5 lipoxygenase 62 lung cancer NSCLC 62 oncogenic mutations 62 invasive ductal carcinomas 62 matrix metalloproteinase 62 perivascular 62 ZNF# 62 BRCA deficient 62 endometrial ovarian 62 estrogen receptor ER 62 pathologic diagnosis 62 acute leukemias 62 JAK2 enzyme 62 COX2 62 hyperplastic polyps 62 SNP rs# [001] 62 lymphangiogenesis 62 caveolin 62 TTR gene 62 noncardiac 62 malignancy 62 unresectable tumors 62 neuroendocrine cells 62 alanine aminotransferase ALT 62 sarcomas 62 hyperoxaluria 62 retroperitoneal 62 NKX#.# 62 gene rearrangements 62 Irinotecan 62 gefitinib Iressa 62 renal cysts 62 colorectum 62 T#I mutant 62 myeloproliferative disorders 62 deacetylation 62 TNFalpha 62 untreated celiac disease 62 PTEN mutations 62 TRAIL R1 62 proteolytic cleavage 62 prostate ovarian 62 basal cell cancers 62 T2 weighted images 62 IL 1β 62 metastatic bladder 62 colon tumors 62 Tumor Necrosis Factor 62 Sjögren syndrome 62 chronic eosinophilic leukemia 62 interleukin IL -# 62 follicular lymphomas 62 gene polymorphism 61 BRCA1 mutations 61 JMML 61 Epstein Barr virus EBV 61 unknown etiology 61 phosphatidylinositol 3 61 IGFBP 61 selective modulator 61 thyrotoxicosis 61 lymphatic tissue 61 pleural mesothelioma 61 gastrointestinal stromal tumors GISTs 61 ErbB2 positive 61 K#R [002] 61 HepG2 cells 61 TNFR1 61 heterozygotes 61 neovascularization 61 brain metastases 61 TNF α 61 interferon IFN 61 hypomethylation 61 chemokine receptors 61 PC# cells 61 granulosa cell 61 EGFr 61 glycosylated 61 plasmacytoid 61 explants 61 bronchogenic carcinoma 61 glioblastoma tumors 61 squamous histology 61 breast cancer subtypes 61 PrPSc 61 polycythemia vera PV 61 osteochondromas 61 differentiated thyroid 61 malignant growths 61 K ras 61 Endometrial cancer 61 bacteriuria 61 oligodendroglioma 61 B7 H3 61 T1a 61 oropharyngeal cancer 61 B Cell Lymphoma 61 ventricular myocardium 61 H#K#me# 61 EUS FNA 61 intracranial tumors 61 #p# [001] 61 follicular lymphoma FL 61 sarcosine 61 PTHrP 61 histologic examination 61 sPLA2 61 leucopenia 61 LDL receptor 61 Non Alcoholic Steatohepatitis 61 non Hodgkin lymphomas 61 IL#B 61 cathepsin B 61 EGF receptors 61 arterial calcification 61 PDGFR 61 liver colon rectal 61 CDKN2A 61 anaplastic lymphoma kinase 61 CsA 61 MLL gene 61 KRAS oncogene 61 anterior uveitis 61 VEGF expression 61 lymph nodes spleen 61 CXCL# 61 qRT PCR 61 BMPR2 61 Brain metastases 61 eccrine 61 TGF ß 61 neuroblastoma cells 61 urine cytology 61 Bcr Abl 61 receptor subtype 61 advanced neoplasia 61 effector function 61 apoptotic pathway 61 cardia 61 histopathologic 61 IGF 1R 61 adrenal cortex 61 coronary stenosis 61 Leydig cells 61 mutational status 61 metalloproteinase 61 CIN3 61 cell lymphoma ALCL 61 aplasia 61 bladder prostate 61 myeloid cells 61 eotaxin 61 BRCA2 mutations 61 Glioblastomas 61 hydronephrosis 61 EoE 61 superficial bladder cancer 61 micronuclei 61 E cadherin expression 61 Cytotoxic T 61 Neutrophil 61 MYCN amplification 61 aneuploidies 61 lichen planus 61 sonographic findings 61 basal cell skin 61 lymphoid malignancies 61 leukoplakia 61 associated lymphoid tissue 61 cytogenetic abnormalities 61 ER alpha 61 dimeric 61 parathyroid carcinoma 61 poorer prognosis 61 eNOS 61 cancerous enlargement 61 elevated triglyceride levels 61 polypoid lesions 61 benign noncancerous 61 prostatic tissue 61 glomerular 61 metastatic cancers 61 pancreatic carcinoma 61 resected 61 phosphate S1P 61 osteoclast 61 intraoperative complications 61 colorectal cancer CRC 61 parathyroid 61 tumorigenicity 61 tyrosine kinase receptor 61 myxoid 61 CCR2 61 intracranial hemorrhage ICH 61 CCR9 61 precancerous condition 61 esophageal adenocarcinoma 61 synovium 61 IgA antibodies 61 tumor subtypes 61 commonly mutated genes 61 metastatic RCC 61 overexpress 61 BRCA2 mutation carriers 61 SGPT 61 metastatic gastric 61 Activating mutations 61 transplantation HSCT 61 prostate colon 61 breast tumors 61 5alpha reductase 61 SCN5A 61 transgene expression 61 histologic 61 biliary tract cancer 61 CYP#B# 61 μg ml 61 hypereosinophilic syndrome 61 recurrent VTE 61 TRAIL receptors 61 Lymphomas 61 nonmelanoma 61 5 HT1A 61 prognostic biomarker 61 cTnT 61 geographic atrophy 61 beta1 integrin 61 esophageal carcinoma 61 pancreatic ovarian 61 squamous cell carcinoma 61 Basal cell carcinoma 61 circulating endothelial cells 61 sinonasal 61 functional polymorphism 61 EGFR mutant 61 hypoperfusion 61 esophageal tumors 61 mediated apoptosis 61 BRAF protein 61 tumors GIST 61 esophageal gastric 61 Rap1 61 immunohistochemical staining 61 nonischemic 61 replicon 61 miRNA genes 61 tyrosine kinase 61 lung nodules 61 #q# [001] 61 CLL SLL 61 catenin 61 proximal tubule 61 parenchyma 61 p# mitogen activated 61 lymphadenectomy 61 HBeAg positive 61 thrombi 61 primary biliary cirrhosis 61 breast lesions 61 germline mutation 61 vWD 61 Helicobacter pylori infection 61 colorectal adenomas 61 herpesviruses 61 c MET 61 FGFs 61 secreted protein 61 chemoresistance 61 pDCs 61 T2 lesions 61 MMP9 61 TCF#L# gene 61 BCL#A 61 demyelination 61 clinicopathologic 61 microdeletions 61 microglial activation 61 imatinib resistant 61 SETDB1 61 carotid plaque 61 EGF receptor 61 HOTAIR 61 Toxicities 61 lymphadenopathy 61 Raf MEK ERK 61 prostate breast 61 ovarian prostate 61 intravenous bisphosphonates 61 alkaline phosphatase 60 chronic HBV infection 60 adrenocortical 60 Squamous cell carcinomas 60 GLUT1 60 prostate carcinomas 60 CCR7 60 recurrent glioblastoma multiforme 60 S#A# [002] 60 IGF IR 60 Mutational 60 BRCA1 BRCA2 60 overexpressed 60 LRAT 60 atherosclerotic disease 60 HER2 amplified 60 prostate bladder 60 ADAMTS# 60 selective agonist 60 hamartoma 60 bone morphogenic protein 60 KCNH2 60 extracellular domain 60 F FDG uptake 60 LHRH receptor positive 60 orchitis 60 pancreatic colon 60 upregulated 60 somatostatin 60 localized renal 60 constitutively expressed 60 pericardial effusion 60 thyroid hormone receptor 60 #p#.# [002] 60 radiosensitivity 60 benign polyps 60 distal colon cancer 60 underwent resection 60 bleomycin 60 endostatin 60 MLL AF9 60 PBMCs 60 renal cortical 60 mutated KRAS 60 precancers 60 metastatic prostate cancer 60 immunohistochemical analysis 60 Genotypes 60 PI3K Akt 60 vulvar intraepithelial neoplasia 60 pyrimidine 60 VUR 60 HAAH 60 Estrogen Receptor 60 eosinophilic 60 troponin T 60 SSc patients 60 E. faecalis 60 tumor necrosis 60 astrocytic 60 mosaicism 60 receptor tyrosine kinase inhibitor 60 hypoxia inducible factor 60 BRAF V#E 60 Ki# 60 FGFR1 60 Metastatic breast cancer 60 Cathepsin B 60 downregulated 60 colon carcinoma 60 aberrantly activated 60 noncancerous cells 60 CREBBP 60 epithelial cells lining 60 nodular 60 molecule epidermal 60 factor HGF 60 carotid plaques 60 AT1R 60 Cysts 60 adhesion molecule 60 cytoplasmic domain 60 total thyroidectomy 60 HER2 neu